Predictive Oncology Inc. (POAI) |
|
0.5005 -0.003 (-0.66%)
|
12-06 10:09 |
|
Open: |
0.5038 |
Pre. Close: |
0.5038 |
|
High:
|
0.515 |
Low:
|
0.5004 |
|
Volume:
|
14,241 |
Market Cap:
|
39(M) |
|
|
|
Technical analysis |
as of: 2022-12-06 9:50:26 AM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.68 One year: 0.8 |
| Support: |
Support1: 0.35 Support2: 0.2 |
| Resistance: |
Resistance1: 0.58 Resistance2: 0.68 |
| Pivot: |
0.36  |
| Moving Average: |
MA(5): 0.48 MA(20): 0.33
MA(100): 0.36 MA(250): 0.58 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 79.7 %D(3): 85.2 |
| RSI: |
RSI(14): 77 |
| 52-week: |
High: 1.1 Low: 0.2 |
| Average Vol(K): |
3-Month: 348 (K) 10-Days: 541 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ POAI ] has closed below upper band by 11.6%. Bollinger Bands are 344.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.59 - 0.59 |
0.59 - 0.6 |
|
Low:
|
0.49 - 0.5 |
0.5 - 0.5 |
|
Close:
|
0.5 - 0.5 |
0.5 - 0.51 |
|
Company Description |
|
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota. |
Headline News |
Sat, 03 Dec 2022
10 Best AI Penny Stocks Under $1 - Yahoo Finance
Fri, 02 Dec 2022
Is Predictive Oncology Inc (POAI) a Good Choice in Medical Instruments & Supplies Friday? - InvestorsObserver
Fri, 25 Nov 2022
Impacts of clouds, aerosols on solar in China, India - pv magazine International
Fri, 11 Nov 2022
Predictive Oncology reports 45% revenue jump, increased gross profit margin in 3Q - Proactive Investors USA
Fri, 11 Nov 2022
Predictive Oncology Inc. (POAI) Q3 2022 Earnings Call Transcript - Seeking Alpha
Tue, 08 Nov 2022
KauaŹ»i voters turnout on Election Day; ballots must be received by 7 p.m. to count - Kauai Now
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Instruments & Supplies |
| Shares Out. |
79 (M) |
| Shares Float |
71 (M) |
|
% Held by Insiders
|
4.1 (%) |
|
% Held by Institutions
|
5.6 (%) |
|
Shares Short
|
201 (K) |
|
Shares Short P.Month
|
197 (K) |
Stock Financials |
|
EPS
|
-0.31 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.37 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-942.6 |
|
Return on Assets (ttm)
|
-22.7 |
|
Return on Equity (ttm)
|
-66.2 |
|
Qtrly Rev. Growth
|
45.2 |
|
Gross Profit (p.s.)
|
0.01 |
|
Sales Per Share
|
0.02 |
|
EBITDA (p.s.)
|
-0.18 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-13 (M) |
|
Levered Free Cash Flow
|
-8 (M) |
Stock Valuations |
|
PE Ratio
|
-1.65 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.33 |
|
Price to Sales
|
24.68 |
|
Price to Cash Flow
|
-3.11 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-10-28 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
